Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

HRMY - Harmony Biosciences Holdings, Inc.... | Finranks

Home

HRMY

(HRMY)

NGM – Цена в реальном времени. Валюта: USD

26.54

-0.90 (-3.28%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

26.55

+0.01 (0.04%)

После закрытия: Mar 27, 2026, 7:13 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL UBS Biotech Summit Date: March 9, 2026 Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Date: March 10, 2026 Location: Miami, FL About Harmony Biosciences Harmony Biosciences is a pharmaceutical co.

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.85 per share a year ago.

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its.

4 Value Stocks to Buy Now Amid AI-Driven Market Volatility

4 Value Stocks to Buy Now Amid AI-Driven Market Volatility

Value stocks are back in focus as markets remain steady. HRMY, TRIP, AES and CNXC screen cheap on P/CF, offering growth and cash flow strength.

Top 5 Bargain P/B Stocks Investors Should Watch Now

Top 5 Bargain P/B Stocks Investors Should Watch Now

AES joins four other low P/B stocks that screen for value, growth and liquidity, offering investors undervalued picks to watch in February.

Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline

Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Видео

No Data

There is no data to display

Пресс-релизы

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its.

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy. WAKIX is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy. “We are excited to achieve this im.

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenue for Q4 and full year 2025 of approximately $243 million and $868 million, respectively. The company continues to build on six consecutive years of revenue growth. On track to extend the pitolisant franchise, Harmony fortifies its profile as a profitable, self-funding biotech company with a robust, late-stage pipeline and strong long-term gro.

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony's Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The collaboration will support Harmony's primary objective of assessing excessive daytime sleepiness (EDS) by complementing traditional patient-reported outcomes, such as the Epworth Sleepiness Scale (ESS), with objective sleep EEG data.